XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.
XNCR · Xencor Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Xencor reported third-quarter revenue of $116.5 million and net income of $39.4 million, versus $21.0 million revenue and a $6.0 million net loss in 2025. It held $555.7 million in cash, cash equivalents and marketable debt securities.
Xencor selected 400 mcg/kg for XmAb819 as the proposed intravenous RP3D after reporting 45.5% cORR, 55% uORR and an 82% 6-month PFS Kaplan-Meier estimate. It plans to discuss a potential accelerated approval pathway with the FDA in 1H2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XNCR
this stock
Xencor Inc
|
$2.66B | +131.2% | +13.7% | — | 17.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$87.10B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 21
XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XNCR | -8.3% | +52.7% | +202.1% | +18.7% | +131.2% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -6.6% | +56.1% | +203.5% | +20.8% | +122.7% |